GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the six-month period ended June 30, 2018 were as follows:



	Codman Specialty Surgical			Orthopedics and Tissue Technologies			Total
	(In thousands)
Goodwill at December 31, 2017	$	634,767		$	303,138		$	937,905
Codman acquisition purchase price allocation adjustments	(3,207		)	—			(3,207		)
Foreign currency translation	(5,101		)	(2,449		)	(7,550		)
Balance, June 30, 2018	$	626,459		$	300,689		$	927,148

The components of the Company’s identifiable intangible assets were as follows:



	June 30, 2018
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	19 years	$	865,467	$	(146,727	)	$	718,740
Customer relationships	13 years	232,312		(98,919		)	133,393
Trademarks/brand names	28 years	104,398		(23,956		)	80,442
Codman trade name	Indefinite	162,900		—			162,900
Supplier relationships	27 years	34,721		(15,805		)	18,916
All other	4 years	11,055		(3,601		)	7,454
		$	1,410,853	$	(289,008	)	$	1,121,845



	December 31, 2017
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	19 years	$	869,174	$	(124,096	)	$	745,078
Customer relationships	13 years	233,430		(91,961		)	141,469
Trademarks/brand names	28 years	104,879		(22,293		)	82,586
Codman trade name	Indefinite	162,900		—			162,900
Supplier relationships	27 years	34,721		(15,092		)	19,629
All other	4 years	11,511		(3,546		)	7,965
		$	1,416,615	$	(256,988	)	$	1,159,627

During the third quarter of 2017, the Company recorded an impairment charge of $3.3 million in cost of goods sold related to completed technology assets acquired from Tarsus Medical, Inc. ("Tarsus Technology"), since the underlying product will no longer be sold. Tarsus Technology was included in the Orthopedic and Tissue Technology segment.

Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired IPR&D) is expected to be approximately $67.0 million in 2018, $66.7 million in 2019, $66.6 million in 2020, $65.6 million in 2021, $62.1 million in 2022, $61.2 million in 2023 and $602.6 million thereafter. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.